Hims & Hers Paves the Way for Global Digital Health Expansion

Hims & Hers (HIMS) is strategically expanding its global digital health presence, marked by the June 2025 acquisition of European platform ZAVA, which adds 1.3 million users and access to the UK, Germany, France, and Ireland. Concurrently, HIMS plans to enter the Canadian market with a low-cost weight loss program utilizing generic semaglutide, aiming to transform chronic care accessibility. These moves underscore HIMS's shift from a U.S.-centric model to a global digital health leader in chronic condition treatment. The company's shares have significantly outperformed, gaining 96.8% year-to-date, with analysts projecting a 177.8% EPS improvement for 2025.

Analysis

Hims & Hers Health, Inc. (HIMS) is executing an aggressive international expansion strategy, positioning itself as a formidable global digital health platform. The acquisition of ZAVA, a European digital health provider, immediately grants HIMS access to 1.3 million active users and established operations in the U.K., Germany, France, and Ireland, leveraging ZAVA's 2.3 million consultations delivered in 2024. This inorganic growth is complemented by a strategic organic move into the Canadian market, timed to capitalize on the debut of generic semaglutide. This allows HIMS to offer a low-cost weight loss program, a significant market opportunity given that nearly two-thirds of Canadian adults face overweight or obesity issues. Financially, HIMS has demonstrated remarkable momentum, with its stock gaining 96.8% year-to-date, substantially outperforming the industry's 6.2% growth. While its forward 12-month price-to-sales ratio of 4.1x is below the industry average of 5.5x, it is considerably higher than its own three-year median of 2.3x, and its 'Value Score of D' suggests valuation may be stretched. This is counterbalanced by a highly positive outlook, with the Zacks Consensus Estimate projecting a 177.8% improvement in earnings per share for 2025, signaling strong growth expectations from the analyst community.

Key Decisions for Investors

• Investors should recognize the dual growth catalysts from the ZAVA acquisition providing immediate European market penetration and the timely entry into the Canadian weight-loss market, which could sustain the company's strong top-line momentum and supports the projected 177.8% EPS growth in 2025.
• Caution is warranted due to the stock's 96.8% year-to-date appreciation and a P/S multiple that, while below the industry average, is significantly above its historical median, indicating potential valuation risk that could limit near-term upside.
• Monitor the execution of the international strategy, paying close attention to the successful integration of ZAVA's operations and the market adoption of the low-cost semaglutide program in Canada, as these are critical to justifying the company's current valuation and achieving its aggressive growth forecasts.